Novartis NVS announced that the FDA has ... the drug for the treatment of adults with C3 glomerulopathy (C3G) to reduce proteinuria. C3G is a progressive and ultra-rare kidney disease that is ...

Novartis has made kidney disorders ... trying to slow disease progression. The lone therapeutic is tolvaptan, brand name Jynarque, an Otsuka Pharmaceutical drug approved by the FDA in 2018 for ...

Novartis has agreed to buy Regulus Therapeutics for up to $1.7 billion, giving the Swiss drugmaker access to an experimental ...

The US FDA has approved a new orphan drug to treat patients with Cushing’s disease who cannot be helped through surgery. Novartis’ Signifor (pasireotide diaspartate) injection has been ...

The FDA has approved Alnylam’s gene silencing drug ... As the kidney function worsens, oxalate can build up and damage other organs including the heart, bones and eyes. The disease is also ...

The U.S. Food and Drug Administration (FDA ... with previously reported data. This is Novartis’s third U.S. approval for its kidney disease portfolio in the last year. Fabhalta was granted FDA ...

(Reuters) -Novartis has agreed to buy Regulus Therapeutics for up to $1.7 billion, giving the Swiss drugmaker access to an experimental drug to treat a life-threatening kidney disease. Under the ...

On Thursday, the U.S. Food and Drug Administration (FDA ... for Fabhalta and its second within the Novartis kidney disease portfolio since August 2024, when Fabhalta was granted accelerated approval ...